Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.65 EUR | -9.07% | -0.36% | +73.77% |
16/05 | Transcript : NewAmsterdam Pharma Company N.V. - Special Call | |
15/05 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.77% | 174.66Cr | |
+8.68% | 12TCr | |
+9.71% | 10TCr | |
-12.00% | 2.27TCr | |
+2.21% | 2.18TCr | |
-10.88% | 1.82TCr | |
-41.90% | 1.65TCr | |
-17.06% | 1.6TCr | |
+1.72% | 1.41TCr | |
+20.88% | 1.07TCr |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk